119 related articles for article (PubMed ID: 27568864)
1. Therapy with eculizumab for patients with CD59 p.Cys89Tyr mutation.
Mevorach D; Reiner I; Grau A; Ilan U; Berkun Y; Ta-Shma A; Elpeleg O; Shorer Z; Edvardson S; Tabib A
Ann Neurol; 2016 Nov; 80(5):708-717. PubMed ID: 27568864
[TBL] [Abstract][Full Text] [Related]
2. Paroxysmal nocturnal hemoglobinuria (PNH) and primary p.Cys89Tyr mutation in CD59: Differences and similarities.
Mevorach D
Mol Immunol; 2015 Sep; 67(1):51-5. PubMed ID: 25818314
[TBL] [Abstract][Full Text] [Related]
3. CD59 deficiency presenting as polyneuropathy and Moyamoya syndrome with endothelial abnormalities of small brain vessels.
Klemann C; Kirschner J; Ammann S; Urbach H; Moske-Eick O; Zieger B; Lorenz MR; Schwarz K; Doostkam S; Ehl S; Korinthenberg R
Eur J Paediatr Neurol; 2018 Sep; 22(5):870-877. PubMed ID: 29843966
[TBL] [Abstract][Full Text] [Related]
4. Devastating recurrent brain ischemic infarctions and retinal disease in pediatric patients with CD59 deficiency.
Ben-Zeev B; Tabib A; Nissenkorn A; Garti BZ; Gomori JM; Nass D; Goldshmidt H; Fellig Y; Anikster Y; Nevo Y; Elpeleg O; Mevorach D
Eur J Paediatr Neurol; 2015 Nov; 19(6):688-93. PubMed ID: 26233519
[TBL] [Abstract][Full Text] [Related]
5. Early-onset chronic axonal neuropathy, strokes, and hemolysis: inherited CD59 deficiency.
Haliloglu G; Maluenda J; Sayinbatur B; Aumont C; Temucin C; Tavil B; Cetin M; Oguz KK; Gut I; Picard V; Melki J; Topaloglu H
Neurology; 2015 Mar; 84(12):1220-4. PubMed ID: 25716358
[TBL] [Abstract][Full Text] [Related]
6. Demyelination, strokes, and eculizumab: Lessons from the congenital CD59 gene mutations.
Tabib A; Karbian N; Mevorach D
Mol Immunol; 2017 Sep; 89():69-72. PubMed ID: 28622911
[TBL] [Abstract][Full Text] [Related]
7. CD59 deficiency is associated with chronic hemolysis and childhood relapsing immune-mediated polyneuropathy.
Nevo Y; Ben-Zeev B; Tabib A; Straussberg R; Anikster Y; Shorer Z; Fattal-Valevski A; Ta-Shma A; Aharoni S; Rabie M; Zenvirt S; Goldshmidt H; Fellig Y; Shaag A; Mevorach D; Elpeleg O
Blood; 2013 Jan; 121(1):129-35. PubMed ID: 23149847
[TBL] [Abstract][Full Text] [Related]
8. Targeted therapy with eculizumab for inherited CD59 deficiency.
Höchsmann B; Dohna-Schwake C; Kyrieleis HA; Pannicke U; Schrezenmeier H
N Engl J Med; 2014 Jan; 370(1):90-2. PubMed ID: 24382084
[No Abstract] [Full Text] [Related]
9. Prothrombotic mechanisms in patients with congenital p.Cys89Tyr mutation in CD59.
Tabib A; Hindi I; Karbian N; Zelig O; Falach B; Mevorach D
Thromb Res; 2018 Aug; 168():67-77. PubMed ID: 29929138
[TBL] [Abstract][Full Text] [Related]
10. Recurrent Demyelinating Episodes as Sole Manifestation of Inherited CD59 Deficiency.
Solmaz I; Aytekin ES; Çağdaş D; Tan C; Tezcan I; Gocmen R; Haliloglu G; Anlar B
Neuropediatrics; 2020 Jun; 51(3):206-210. PubMed ID: 31752029
[TBL] [Abstract][Full Text] [Related]
11. Perisurgical induction of eculizumab in a patient with paroxysmal nocturnal hemoglobinuria: its inhibition of surgery-triggered hemolysis and the consequence of subsequent discontinuation.
Kurita N; Obara N; Fukuda K; Nishikii H; Sato S; Inagawa S; Kurokawa T; Owada Y; Ninomiya H; Chiba S
Blood Coagul Fibrinolysis; 2013 Sep; 24(6):658-62. PubMed ID: 23917586
[TBL] [Abstract][Full Text] [Related]
12. Optic neuritis in CD59 deficiency: an extremely rare presentation.
Günay Ç; Yardım E; Yaşar E; Hız-Kurul AS; Uzan GS; Öztürk T; Yaman A; Yiş U
Turk J Pediatr; 2022; 64(4):787-794. PubMed ID: 36082655
[TBL] [Abstract][Full Text] [Related]
13. Effect of eculizumab on hemolysis and transfusion requirements in patients with paroxysmal nocturnal hemoglobinuria.
Hillmen P; Hall C; Marsh JC; Elebute M; Bombara MP; Petro BE; Cullen MJ; Richards SJ; Rollins SA; Mojcik CF; Rother RP
N Engl J Med; 2004 Feb; 350(6):552-9. PubMed ID: 14762182
[TBL] [Abstract][Full Text] [Related]
14. Paroxysmal nocturnal hemoglobinuria: a complement-mediated hemolytic anemia.
DeZern AE; Brodsky RA
Hematol Oncol Clin North Am; 2015 Jun; 29(3):479-94. PubMed ID: 26043387
[TBL] [Abstract][Full Text] [Related]
15. Shiga toxin-induced complement-mediated hemolysis and release of complement-coated red blood cell-derived microvesicles in hemolytic uremic syndrome.
Arvidsson I; Ståhl AL; Hedström MM; Kristoffersson AC; Rylander C; Westman JS; Storry JR; Olsson ML; Karpman D
J Immunol; 2015 Mar; 194(5):2309-18. PubMed ID: 25637016
[TBL] [Abstract][Full Text] [Related]
16. Eculizumab in AQP4-IgG-positive relapsing neuromyelitis optica spectrum disorders: an open-label pilot study.
Pittock SJ; Lennon VA; McKeon A; Mandrekar J; Weinshenker BG; Lucchinetti CF; O'Toole O; Wingerchuk DM
Lancet Neurol; 2013 Jun; 12(6):554-62. PubMed ID: 23623397
[TBL] [Abstract][Full Text] [Related]
17. The complement inhibitor eculizumab in paroxysmal nocturnal hemoglobinuria.
Hillmen P; Young NS; Schubert J; Brodsky RA; Socié G; Muus P; Röth A; Szer J; Elebute MO; Nakamura R; Browne P; Risitano AM; Hill A; Schrezenmeier H; Fu CL; Maciejewski J; Rollins SA; Mojcik CF; Rother RP; Luzzatto L
N Engl J Med; 2006 Sep; 355(12):1233-43. PubMed ID: 16990386
[TBL] [Abstract][Full Text] [Related]
18. Eculizumab: a guide to its use in paroxysmal nocturnal hemoglobinuria.
Keating GM; Lyseng-Williamson KA; McKeage K
BioDrugs; 2012 Apr; 26(2):125-30. PubMed ID: 22350448
[TBL] [Abstract][Full Text] [Related]
19. CD55 and CD59 deficiency in transplant patient populations: possible association with paroxysmal nocturnal hemoglobinuria-like symptoms in Campath-treated patients.
Ruiz P; Weppler D; Tryphonopoulos P; Nishida S; Moon J; Kato T; Selvaggi G; Levi D; Madariaga J; DelaGarza J; Tuteja S; Garcia M; Tzakis A
Transplant Proc; 2006; 38(6):1750-2. PubMed ID: 16908271
[TBL] [Abstract][Full Text] [Related]
20. Eculizumab effect on the hemostatic state in patients with paroxysmal nocturnal hemoglobinuria.
Seregina EA; Tsvetaeva NV; Nikulina OF; Zapariy AP; Erasov AV; Gribkova IV; Orel EB; Ataullakhanov FI; Balandina AN
Blood Cells Mol Dis; 2015 Feb; 54(2):144-50. PubMed ID: 25497169
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
